Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?
Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately,...
Gespeichert in:
| Veröffentlicht in: | World journal of gastrointestinal oncology 2024-12, Vol.16 (12), p.4753-4756 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4756 |
|---|---|
| container_issue | 12 |
| container_start_page | 4753 |
| container_title | World journal of gastrointestinal oncology |
| container_volume | 16 |
| creator | Centrone, Natalia Serrano Uson Junior, Pedro Luiz |
| description | Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field. |
| doi_str_mv | 10.4251/wjgo.v16.i12.4753 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11577365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3146853965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</originalsourceid><addsrcrecordid>eNpVkd9uFSEQxjdGY5vaB_DGcOmF5wgL7J-rxpxYNWnijV6TgZ3tUllYgT2Nvo1vWtbWpnIBQ_jmmxl-VfWa0b2oJXt_e3Md9kfW7C2r96KV_Fl1ynrR7WRNxfMn8Ul1ntINLUuIljL6sjrhfdN2HZWn1Z9DmLX1kG3wiYSROPTHcvNWE_ADsfO8eiRmQvNjCdZnYv1ktc0hJrK4NZEcwSeIGaMFtwnngLMOzv7-a_qO2ERsJnlCskQ7I8nbNoZIVh8xocmgHZIJF8jBoHOrg0gMRGN9mOHiVfViBJfw_OE8q75ffvx2-Ly7-vrpy-HD1c7UvM87jSCGTvS04T1va1MbaHXdDbIEnW6BMVZTQGZa08CIQ9MBSN5IpvuxL2p-Vl3c-y6rnnEw6MtkTm09Q_ylAlj1_4u3k7oOR8WYbNviVBzePjjE8HPFlNVs0zYReAxrUpyJppPl7zcpu5eaGFKKOD7WYVRteNWGVxW8quBVG96S8-Zpg48Z_2DyO0pEqS4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146853965</pqid></control><display><type>article</type><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</creator><creatorcontrib>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</creatorcontrib><description>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</description><identifier>ISSN: 1948-5204</identifier><identifier>EISSN: 1948-5204</identifier><identifier>DOI: 10.4251/wjgo.v16.i12.4753</identifier><identifier>PMID: 39678805</identifier><language>eng</language><publisher>China: Baishideng Publishing Group Inc</publisher><subject>Letter to the Editor</subject><ispartof>World journal of gastrointestinal oncology, 2024-12, Vol.16 (12), p.4753-4756</ispartof><rights>The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</rights><rights>The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577365/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577365/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39678805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Centrone, Natalia</creatorcontrib><creatorcontrib>Serrano Uson Junior, Pedro Luiz</creatorcontrib><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><title>World journal of gastrointestinal oncology</title><addtitle>World J Gastrointest Oncol</addtitle><description>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</description><subject>Letter to the Editor</subject><issn>1948-5204</issn><issn>1948-5204</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkd9uFSEQxjdGY5vaB_DGcOmF5wgL7J-rxpxYNWnijV6TgZ3tUllYgT2Nvo1vWtbWpnIBQ_jmmxl-VfWa0b2oJXt_e3Md9kfW7C2r96KV_Fl1ynrR7WRNxfMn8Ul1ntINLUuIljL6sjrhfdN2HZWn1Z9DmLX1kG3wiYSROPTHcvNWE_ADsfO8eiRmQvNjCdZnYv1ktc0hJrK4NZEcwSeIGaMFtwnngLMOzv7-a_qO2ERsJnlCskQ7I8nbNoZIVh8xocmgHZIJF8jBoHOrg0gMRGN9mOHiVfViBJfw_OE8q75ffvx2-Ly7-vrpy-HD1c7UvM87jSCGTvS04T1va1MbaHXdDbIEnW6BMVZTQGZa08CIQ9MBSN5IpvuxL2p-Vl3c-y6rnnEw6MtkTm09Q_ylAlj1_4u3k7oOR8WYbNviVBzePjjE8HPFlNVs0zYReAxrUpyJppPl7zcpu5eaGFKKOD7WYVRteNWGVxW8quBVG96S8-Zpg48Z_2DyO0pEqS4</recordid><startdate>20241215</startdate><enddate>20241215</enddate><creator>Centrone, Natalia</creator><creator>Serrano Uson Junior, Pedro Luiz</creator><general>Baishideng Publishing Group Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20241215</creationdate><title>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</title><author>Centrone, Natalia ; Serrano Uson Junior, Pedro Luiz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c239t-bea4d8490639372c2ca7b28d52ca8b7a11120ae1c7c6afed68aa53651b9f9c2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Letter to the Editor</topic><toplevel>online_resources</toplevel><creatorcontrib>Centrone, Natalia</creatorcontrib><creatorcontrib>Serrano Uson Junior, Pedro Luiz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Centrone, Natalia</au><au>Serrano Uson Junior, Pedro Luiz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma?</atitle><jtitle>World journal of gastrointestinal oncology</jtitle><addtitle>World J Gastrointest Oncol</addtitle><date>2024-12-15</date><risdate>2024</risdate><volume>16</volume><issue>12</issue><spage>4753</spage><epage>4756</epage><pages>4753-4756</pages><issn>1948-5204</issn><eissn>1948-5204</eissn><abstract>Hepatocellular carcinoma (HCC) is a lethal disease and unfortunately, most patients will be diagnosed with unresectable/advanced stages and the overall prognosis is poor. For patients with initially unresectable HCC (uHCC), transarterial chemoembolization (TACE) was the mainstream treatment. Lately, the incorporation of immune checkpoint inhibitors and antiangiogenics for the treatment of metastatic disease has paved the way for significant improvements in the treatment of initially uHCC. In this editorial we will discuss an article that evaluated ICI combinations with lenvatinib and TACE for the treatment of uHCC patients, and highlight future advances in the field.</abstract><cop>China</cop><pub>Baishideng Publishing Group Inc</pub><pmid>39678805</pmid><doi>10.4251/wjgo.v16.i12.4753</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-5204 |
| ispartof | World journal of gastrointestinal oncology, 2024-12, Vol.16 (12), p.4753-4756 |
| issn | 1948-5204 1948-5204 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11577365 |
| source | Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Letter to the Editor |
| title | Combinations of lenvatinib and immune checkpoint inhibitors plus transarterial chemoembolization, is it the prime time for unresectable hepatocellular carcinoma? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A54%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combinations%20of%20lenvatinib%20and%20immune%20checkpoint%20inhibitors%20plus%20transarterial%20chemoembolization,%20is%20it%20the%20prime%20time%20for%20unresectable%20hepatocellular%20carcinoma?&rft.jtitle=World%20journal%20of%20gastrointestinal%20oncology&rft.au=Centrone,%20Natalia&rft.date=2024-12-15&rft.volume=16&rft.issue=12&rft.spage=4753&rft.epage=4756&rft.pages=4753-4756&rft.issn=1948-5204&rft.eissn=1948-5204&rft_id=info:doi/10.4251/wjgo.v16.i12.4753&rft_dat=%3Cproquest_pubme%3E3146853965%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146853965&rft_id=info:pmid/39678805&rfr_iscdi=true |